Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Crinetics Pharmaceuticals, maintaining a $90 price target. Analyst Josh Schimmer continues to see potential in the company's stock.
September 16, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Crinetics Pharmaceuticals, maintaining a $90 price target. Analyst Josh Schimmer continues to see potential in the company's stock.
The reiteration of an Overweight rating and a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100